Navigation Links
Schering-Plough Reschedules Time of Conference Call, Webcast for 2008 Second Quarter Earnings to Later Today
Date:7/21/2008

KENILWORTH, N.J., July 21 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) has rescheduled the time of its conference call and webcast to review the sales and earnings results for the 2008 second quarter to approximately 4:45 p.m. (EDT) from 8 a.m. today. The quarterly financial results will be issued today, July 21, 2008, after the close of the New York Stock Exchange.

Schering-Plough made the second-quarter earnings schedule change because Terje Pedersen, M.D., Ph.D., Chief, Preventive Medicine Clinic, Ulleval University Hospital, Oslo, Norway, and the primary investigator of Simvastatin plus Ezetimibe in Aortic Stenosis study (SEAS), has announced that he will present an update on the study at 1 p.m. (U.S. EDT) today.

To listen live to the Schering-Plough second quarter earnings conference call, dial 1-877-565-9664 or 1-706-634-5003 and enter conference ID #50992673. A replay of the call will be available beginning later on July 21 through 5 p.m. on July 28. To listen to the replay, dial 1-800-642-1687 or 1-706-645-9291 and enter the conference ID #50992673. A live audio webcast of the conference call also will be available by going to the Investor Relations section of the Schering-Plough corporate Web site, http://www.schering-plough.com, and clicking on the "Presentations/Webcasts" link. A replay of the webcast will be available starting on July 21 through 5 p.m. on Aug. 20.

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies i
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Schering-Plough Announces Closing of Planned Divestiture of Selected Animal Health Products
2. Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
3. Schering-Plough Schedules Conference Call and Webcast for 2008 Second Quarter Earnings
4. Schering-Plough Appoints Janet M. Barth Vice President, Investor Relations
5. Schering-Plough Schedules Webcast for Annual Meeting of Shareholders
6. Intervet/Schering-Plough Animal Health Outlines Strength of the Combination
7. Schering-Plough/MERCK Pharmaceuticals Receives Not-Approvable Letter from FDA for Loratadine/Montelukast
8. Schering-Plough CEO Buys $2 Million in Common Shares
9. Schering-Plough Announces Planned Divestiture of Select Animal Health Products in Europe
10. Schering-Plough Reports Financial Results for First Quarter of 2008
11. Schering-Plough Schedules Conference Call and Webcast for 2008 First Quarter Earnings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... December 17, 2014 Achim Noack has ... for Stoller Group. In this position, Noack will assist ... administrative matters, develop marketing strategy and supervise global marketing ... , “Achim has tremendous knowledge and experience in the ... Group. “His experience and innovative thinking will be a ...
(Date:12/17/2014)... Xeno Diagnostics has again received ... recent COLA inspection. Xeno has met all criteria ... accreditation organization. Accreditation is earned only by laboratories ... operations, demonstrate continued accuracy in the performance of ... survey. , While the Laboratory Excellence ...
(Date:12/17/2014)... , Dec. 17, 2014  United Therapeutics Corporation (NASDAQ: ... promotions as well as changes to Martine Rothblatt ... Promotions United Therapeutics announced the promotion ... Co-Chief Executive Officer and David Zaccardelli , Pharm.D. ... connection with these promotions, Dr. Rothblatt,s title will change ...
(Date:12/15/2014)... 2014 METTLER TOLEDO is pleased ... ParticleView V19 with PVM technology , is ... vision and measurement tool continuously captures high-resolution images ... V19 then automatically prepares a report pairing the ... and concentration changes. This compelling blend of high ...
Breaking Biology Technology:Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2
... Sales in the Third Quarter up by 7.2% to EUR268.0m, ... Third Quarter of 2008,From EUR7.4m to EUR16.5m, - Sales ... Axel Herberg Confirms the Outlook for 2008, Gerresheimer AG ... the third quarter of 2008. Overall, sales by the,globally operating ...
... October 2008] Recent research from the Swedish medical university ... stem cells discoveries that contradict previous findings. The ... show amongst other things, that hair follicle stem cells ... tissue. , "The stem cells don,t behave ...
... Based on its recent,analysis of the bone healing ... the 2008 North American Frost & Sullivan Award ... Extender and Substitute,scaffold. InQu represents the first commercial ... platform technology., Although spinal fusions and other ...
Cached Biology Technology:Gerresheimer Substantially Increases Quarterly Operating Profit 2Gerresheimer Substantially Increases Quarterly Operating Profit 3Gerresheimer Substantially Increases Quarterly Operating Profit 4Gerresheimer Substantially Increases Quarterly Operating Profit 5Frost & Sullivan Acknowledges ISTO Technologies' Role in Developing Advanced Biologic Products for Bone Healing 2Frost & Sullivan Acknowledges ISTO Technologies' Role in Developing Advanced Biologic Products for Bone Healing 3Frost & Sullivan Acknowledges ISTO Technologies' Role in Developing Advanced Biologic Products for Bone Healing 4
(Date:12/17/2014)... Dec. 16, 2014 Valencell, a leader in ... biometric technology to industry leaders such as Intel, Jabra, ... validated, biometric wearable products. These products will be showcased ... Las Vegas . "Our ... flexible and robust – with the clinical data to ...
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition ... Region 2015-2019"  report to their offering. ... is advances in technology. With continuous advances in ... to the latest standard that meets the needs ...
(Date:12/10/2014)... You,ve been here before: you desperately need to ... password, site key or the answer to your secret question. ... Today, Hoyos Labs , a digital ... finally put an end to the frustration that comes with ... 1U leverages a user,s smartphone to acquire his or her ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... N.C. By altering the genetic makeup of normally ... cells capable of generating and passing electrical current. ... treating diseases of the nervous system or the heart, ... to communicate with adjacent cells in order to function ...
... gene therapy into an arterial wall effectively protects the ... The promising results, published July 19 in the journal ... In atherosclerosis, fatty lesions called plaques form ... narrows arteries, thereby restricting blood flow and causing chest ...
... and Providence cities scattered across the eastern half ... all have coal-fired power plants. A new study from ... is among the first to investigate mercury deposits in ... The study, which appears in the July 2011 issue ...
Cached Biology News:Engineering excitable cells for studies of bioelectricity and cell therapy 2Engineering excitable cells for studies of bioelectricity and cell therapy 3Gene therapy delivered once to blood vessel wall protects against atherosclerosis in rabbit studies 2Gene therapy delivered once to blood vessel wall protects against atherosclerosis in rabbit studies 3Gene therapy delivered once to blood vessel wall protects against atherosclerosis in rabbit studies 4Soil samples reveal urban mercury footprints 2
anti-JNK2 Immunogen: Recombinant human JNK2 protein Accession Number: NM_002752 Quality Assurance: Routinely evaluated by immunoblot. Molecular Weight: 46 and/or 54 kDa Available ...
... Synthetic peptide derived from the C-terminal region ... kinase C zeta isoform (PKCzeta). Specificity: ... protein. Recognizes PKCzeta and PKMzeta (PKCzeta ... Reactivity: Mouse Rat (positive controls: mouse ...
Lipid-rich bovine serum albumin for cell culture. It is chromatographically purified and has an IgG content 1.0% (w/w)....
Request Info...
Biology Products: